The Board of Directors of Idogen AB ("Idogen" or the "Company") has resolved that the record date for the consolidation of shares, that was resolved on the Annual General Meeting on May 12, 2020, shall be May 28, 2020.
The Annual General Meeting of Idogen on May 12, 2020 resolved on a consolidation of shares 1:10, which implies that ten (10) existing shares will be consolidated into one (1) share. The Board of Directors of Idogen has, in accordance with the resolution at the Annual General Meeting, determined that the record date for the consolidation shall be May 28, 2020. The last day of trading in the Idogen share before the consolidation is May 26, 2020 and the first day of trading in the Idogen share after the consolidation is on May 27, 2020.Following the consolidation, the number of shares in the Company will amount to a total of 9,121,654 shares, each with a quota value of SEK 0.70. As a result of the consolidation, the ISIN code for Idogens share will change. As of May 27, 2020, the Idogen share will trade with the new ISIN code SE0014428561.
For the completion of the consolidation, one of the Company's major shareholders, Hans-Olov Sjögren, has undertaken to, to those shareholders whose holdings are not evenly divisible by ten (10), free of charge provide the number of shares required for the holding to be evenly divisible by the consolidation quota. These equalization shares will also include the seven (7) shares subscribed for by Erik Penser Bank AB (publ) in accordance with resolution at the Annual General Meeting on May 12, 2020. The delivery of shares will take place through Euroclear Sweden AB's provision without the need for any action to be taken by the Company's shareholders.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Tel: +46 70 918 00 10
The information was submitted for publication, through the agency of the contact persons set out above, on May 20, 2020.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of haemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.